Shots:
- Gyre has entered into an agreement to acquire Cullgen in an all-stock transaction valued at ~$300M, making it a wholly owned subsidiary upon deal completion in Q2’26
- Following the acquisition’s close, the combined company will operate as a fully integrated biopharma organization with US & China capabilities across discovery, manufacturing, & commercialization, addressing inflammatory diseases, cancer, pain, & other therapeutic areas
- Additionally, following a supportive pre-NDA meeting with China’s CDE, Gyre plans to file Hydronidone for conditional approval in H1’26 & conduct a P-IIIc trial for full approval, while adding Cullgen’s TPD/DAC platform
Ref: Globenewswire | Image: Cullgen | Press Release
Related News: Gilead Sciences to Acquire Arcellx for $7.8B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
